For individuals battling Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a devastating condition, the emergence of Vyndamax and the formulated version represents a true breakthrough . These groundbreaking therapies protect the transthyretin protein, halting its damaging build-up and lessening the